<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05051761</url>
  </required_header>
  <id_info>
    <org_study_id>ZGJAK018</org_study_id>
    <nct_id>NCT05051761</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata</brief_title>
  <acronym>AA</acronym>
  <official_title>A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Jaktinib in Adult Patients With Severe Alopecia Areata</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suzhou Zelgen Biopharmaceuticals Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suzhou Zelgen Biopharmaceuticals Co.,Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center Phase 3 study to evaluate the safety and effectiveness of an&#xD;
      investigational study drug (called Jaktinib) in adults (≥18 years and &lt;65 years) who have 50%&#xD;
      or greater scalp hair loss. The study is placebo-controlled, meaning that some patients&#xD;
      entering the study will not receive active study drug but will receive tablets with no active&#xD;
      ingredients (a placebo). It is double-blinded, meaning that the Sponsor, the study doctors,&#xD;
      the staff, and the patients will not know whether a patient is on active study drug (or the&#xD;
      dose) or placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Severity of Alopecia Tool (SALT) ≤ 20</measure>
    <time_frame>Week 24</time_frame>
    <description>SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving 50% Improvement of SALT (SALT50)</measure>
    <time_frame>Week 24</time_frame>
    <description>Percentage of participants achieving SALT50</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">390</enrollment>
  <condition>Alopecia Areata</condition>
  <arm_group>
    <arm_group_label>Jaktinib 50mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Jaktinib administered orally. Placebo administered orally to maintain the blind.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Jaktinib 75mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Jaktinib administered orally. Placebo administered orally to maintain the blind.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Jaktinib</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>Jaktinib 50mg BID</arm_group_label>
    <arm_group_label>Jaktinib 75mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects voluntarily sign the informed consent form (ICF);&#xD;
&#xD;
          -  Age ≥ 18 years and &lt;65 years, either male or female;&#xD;
&#xD;
          -  Clinical presentation compatible with alopecia areata with a current episode lasting&#xD;
             not exceeding ≤8 years.&#xD;
&#xD;
          -  At least 50% scalp hair loss.&#xD;
&#xD;
          -  Willing to comply with the study visits and requirements of the study protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has taken a JAK inhibitor prior to randomization;&#xD;
&#xD;
          -  Subjects who are unsuitable to the trial, as identified by the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianzhong Zhang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University People's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Qianjin Lu, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital for skin diseases, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qianjin Lu, PhD</last_name>
    <phone>+86-0731-85295999</phone>
    <email>qianlu5860@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>No. 12, Jiangwangmiao Street, Xuanwu District</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210042</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Qianjin Lu, PhD</last_name>
      <phone>+8673185295999</phone>
      <email>qianlu5860@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 11, 2021</study_first_submitted>
  <study_first_submitted_qc>September 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2021</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

